IPO hopeful rEVO puts off its plans for a $75M debut

Massachusetts biotech rEVO Biologics is postponing its efforts to go public in a $75 million IPO. The company, formerly called GTC Therapeutics, had planned to spend its haul on developing its lead drug, ATryn, to treat preeclampsia. More